Loading...
•
Jun 30
OptimizeRx Q2 2025 Earnings Report
OptimizeRx reported strong second quarter 2025 financial results, with significant increases in revenue, gross profit, and net income, and updated its fiscal year 2025 guidance upwards.
Key Takeaways
OptimizeRx delivered a robust second quarter in 2025, with revenue increasing by 55% year-over-year to $29.2 million and gross profit rising by 59% to $18.6 million. The company achieved GAAP net income of $1.5 million and non-GAAP net income of $4.5 million, demonstrating a significant turnaround from a net loss in the prior year. OptimizeRx also strengthened its financial position by paying down $4.5 million of principal on its outstanding term loan and raised its full-year 2025 guidance for both revenue and adjusted EBITDA.
Revenue for Q2 2025 increased by 55% year-over-year, reaching $29.2 million.
Gross profit for Q2 2025 grew by 59% year-over-year to $18.6 million.
The company reported a GAAP net income of $1.5 million ($0.08 per share) and a non-GAAP net income of $4.5 million ($0.24 per diluted share) for the quarter.
OptimizeRx paid down $4.5 million of principal on its outstanding term loan, exceeding its scheduled debt payment.
OptimizeRx
OptimizeRx
Forward Guidance
OptimizeRx increased its full-year 2025 guidance, expecting revenue between $104 million and $108 million and Adjusted EBITDA between $14.5 million and $17.5 million, reflecting strong performance and a positive outlook.
Positive Outlook
- Increased full-year 2025 revenue guidance to a range of $104 million to $108 million.
- Increased full-year 2025 Adjusted EBITDA guidance to a range of $14.5 million to $17.5 million.
- Year-to-date results are delivering profitable growth ahead of expectations.
- Contracted revenue is up more than 30% year-over-year, indicating strong future performance.
- Company is well on its way to becoming a 'Rule of 40' company.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the report.
- The company did not provide GAAP guidance for Adjusted EBITDA due to the uncertainty and variability of certain components.
- Future performance is subject to various risks and uncertainties, including government regulation and competition.
- Dependence on a concentrated group of customers could pose a risk.
- Cybersecurity incidents could disrupt operations.